Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

for
Solid Tumor, MET Alteration
Location: Washington D.C. DC, Canton OH, Nashville TN
Sponsor: Pierre Fabre Medicament

Sex: All

Age: 18+

Code: NCT06669117

Phase 1, Phase 2, Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

for
Advanced Solid Tumor
Location: Denver CO, San Antonio TX, Duarte CA, LA CA,
Sponsor: ABL Bio, Inc.

Sex: All

Age: 18+

Code: NCT04762641

Phase 1, Recruiting

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

for
Advanced Solid Tumors
Location: New York NY, Fairfax VA, Margate FL, Plantation FL,
Sponsor: DualityBio Inc.

Sex: All

Age: 18+

Code: NCT05914116

Phase 1, Phase 2, Recruiting

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

for
Hematopoietic and Lymphoid Cell Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT02464696

Recruiting

Virtual Reality Therapy for Cancer-Treatment Associated Symptoms

for
Cancer, Cancer Pain, Virtual Reality
Location: Baltimore MD
Sponsor: University of Maryland, Baltimore

Sex: All

Age: 18 - 70+

Code: NCT06248216

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Cancer and Mild Cognitive Impairment Dyadic Intervention

for
Cancer, Cognitive Impairment
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18 - 70+

Code: NCT05144516

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for
Breast Cancer
Location: Boston MA, New Haven CT, Stony Brook NY, New York NY,
Sponsor: Greenwich LifeSciences, Inc.

Sex: All

Age: 18 - 70+

Code: NCT05232916

Phase 3, Recruiting

Communication Issues in Patient and Provider Discussions of Immunotherapy

for
Hematopoietic and Lymphoid System Neoplasm,
Location: Decatur GA, Atlanta GA
Sponsor: Emory University

Sex: All

Age: 0+

Code: NCT05873608

Recruiting

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

for
Metastatic Cancer
Location: Sacramento CA
Sponsor: University of California, Davis

Sex: All

Age: 18+

Code: NCT06389123

Phase 1, Recruiting

Weighted Blanket Use to Reduce Anxiety in Oncology Patients

for
Hematopoietic and Lymphoid Cell Neoplasm,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06089408

Recruiting

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

for
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer,
Location: Philadelphia PA, Memphis TN, Houston TX, Seattle WA,
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 2 - 70+

Code: NCT05783323

Phase 2, Recruiting

Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy

for
Chemotherapy-Induced Peripheral Neuropathy,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05411523

Recruiting

A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

for
Breast Cancer
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT06327490

Phase 2, Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

for
Solid Tumors, GI Cancer
Location: Boston MA, Baltimore MD, Washington DC, Durham NC,
Sponsor: Curegenix Inc.

Sex: All

Age: 18+

Code: NCT02675946

Phase 1, Recruiting

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Boston MA, New York NY, Philadelphia PA, Fairfax VA,
Sponsor: Pyxis Oncology, Inc

Sex: All

Age: 18+

Code: NCT06795412

Phase 1, Phase 2, Recruiting

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

for
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer,
Location: Miami FL, Atlanta GA, Fairway KS
Sponsor: Reshma L. Mahtani, D.O.

Sex: All

Age: 18+

Code: NCT06263543

Phase 2, Recruiting

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

for
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Location: Miami FL, Orlando FL
Sponsor: University of Central Florida

Sex: All

Age: 60+

Code: NCT05838638

Recruiting

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis

for
Breast Cancer
Location: Tampa FL, Hilo HI, Honolulu HI
Sponsor: University of Hawaii

Sex: Female

Age: 20 - 70+

Code: NCT05369546

Recruiting

Patient Recall of Cancer Screening and Diagnosis

for
Breast Cancer, Prostate Cancer
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT05014295

Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

for
HER2-positive Breast Cancer
Location: Lee's Summit MO, Kansas City MO, Kansas City KS,
Sponsor: Qamar Khan

Sex: Female

Age: 18+

Code: NCT03238495

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial